Addex invests CHF 2 million in Stalicla for neurological disorders precision medicine

From GlobeNewswire: 2025-06-30 01:00:00

Addex Therapeutics, a biopharmaceutical company, invests CHF 2 million in Stalicla, a company focusing on precision medicine for neurological disorders. Addex CEO appointed to Stalicla’s Board of Directors. Stalicla to use funding for autism drug candidates and general corporate activities. Stalicla preparing for Phase 2 trials for autism candidates and advancing mavoglurant program for cocaine use disorders. Addex aims to support precision therapeutics in CNS disorders. Stalicla raised over $50m for NDD treatments and plans to initiate Phase 2 trials for its leading NDD asset, STP1, along with a second asset targeting specific subpopulations within autism. STP7 progressing towards Phase 3 trials with full funding from US government. Addex focuses on developing novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant, under evaluation for brain injury recovery. Addex also holds 20% equity interest in Neurosterix LLC, advancing allosteric modulator programs for various disorders. Addex shares listed on SIX Swiss Exchange and NASDAQ Capital Market under ticker symbol “ADXN.”



Read more at GlobeNewswire: Addex Leads CHF 2 Million Investment in Stalicla to Advance